Form 4: NewAmsterdam Pharma Director James N. Topper Acquires Shares
SEC Form 4 Filing
Director James N. Topper reports acquisition of NewAmsterdam Pharma Co N.V. shares through Frazier Life Sciences.
Summary
- On March 26, 2024, James N. Topper, a director of NewAmsterdam Pharma Co N.V., acquired 8,429 ordinary shares at a price of $21.5 per share.
- These shares were acquired indirectly through Frazier Life Sciences X, L.P.
- Topper also indirectly holds 3,801,000 shares through Frazier Lifesciences Sponsor LLC.
- Following the transaction, Topper indirectly owns 3,008,429 shares through Frazier Life Sciences X, L.P.
- Topper disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Sentiment
Score: 5
Explanation: This is a neutral report of a transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares in their own company. It provides transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence, as it signals that a director is investing in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/26/2024 | Date of transaction: Acquisition of ordinary shares. |
| 03/28/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.